Studies on the Toxicity of MPTP to Dopamine Neurons in Tissue and Cell Cultures

  • Catherine Mytilineou
  • Linda K. Friedman
  • Peter Danias


1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin with high specificity for the dopamine (DA) neurons of the nigrostriatal pathway of humans (Davis et al., 1979), monkeys (Burns et al., 1983) and mice (Heikkila et al., 1984a). In humans, the lesion which results from MPTP toxicity produces symptoms similar to idiopathic parkinsonism (Langston et al., 1983). The etiology of idiopathic parkinsonism remains still unknown and it is hoped that study of MPTP induced parkinsonism can elucidate the causes of this disease. Although it is possible that idiopathic parkinsonism bears no relationship with MPTP intoxication, knowledge of the cellular and molecular events that occur during MPTP induced neuronal degeneration would be a significant contribution to our understanding of neuronal susceptibility to environmental and/or endogenous neurotoxins.


Monoamine Oxidase Dopamine Neuron Idiopathic Parkinsonism Dopaminergic Neurotoxicity Mesencephalic Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M. and Kopin, I. J. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A., 80:4546–4550.PubMedCrossRefGoogle Scholar
  2. Castagnoli, N., Chiba, K. and Trevor, A.J. (1985) Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 36:225–230.PubMedCrossRefGoogle Scholar
  3. Chiba, K., Trevor, A. and Castagnoli, N., Jr. (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:574–578.PubMedCrossRefGoogle Scholar
  4. Chiba, K., Trevor, A.J. and Castagnoli, N., Jr. (1985) Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem. Biophys. Res. Commun. 128:1228–1232, 1985.PubMedCrossRefGoogle Scholar
  5. Cohen, G., Pasik, P.,.Cohen, B., Leist, A., Mytilineou, C. and Yahr, M. D. (1984) Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol., 106:209–210.PubMedCrossRefGoogle Scholar
  6. Cohen, G. and Mytilineou, C. (1985) Studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 36:237–242.PubMedCrossRefGoogle Scholar
  7. Davis, G.C., Williams, A.C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M. and Kopin, I.J. (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat. Res. 1:249–254.CrossRefGoogle Scholar
  8. Friedman, L. and Mytilineou, C. (1987) The toxicity of MPTP to dopamine neurons in culture is reduced at high concentrations. Neurosci. Lett. 79:65–72.PubMedCrossRefGoogle Scholar
  9. Fuller, R. and Hemrick-Luecke, S.K. (1985) Mechanisms of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity to striatal dopamine neurons in mice. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 9:687–690.CrossRefGoogle Scholar
  10. Glover, V., Gibb, C. and Sandler, M. (1986) Monoamine oxidase B (MAO-B) is the major catalyst for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation in human brain and other tissues. Neurosci. Lett. 64:216–220.PubMedCrossRefGoogle Scholar
  11. Heikkila, R. E., Hess, A. and Duvoisin, R. (1984a) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science, 224:1451–1453.PubMedCrossRefGoogle Scholar
  12. Heikkila, R. E., Manzino. L., Cabbat, F. S. and Duvoisin, R. C. (1984b) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature, 311: 467–469.PubMedCrossRefGoogle Scholar
  13. Irwin, I. (1986) The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A key to Parkinson’s disease? Pharmaceut. Res. 3:7–11, 1986.CrossRefGoogle Scholar
  14. Javitch, J.A. and Snyder, S.H. (1985) Uptake of MPP (+) by dopamine neurons explains selectivity of parkin-sonism-inducing neurotoxin, MPTP. Eur. J. Pharmacol. 106:445–456.Google Scholar
  15. Javitch, J. A., D’Amato, R. J., Strittmatter, S. M. and Snyder, S. H. (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U.S.A., 82:2173–2177.PubMedCrossRefGoogle Scholar
  16. Johannessen, J.N., Adams, J.D., Schuller, H.M., Bacon, J.P. and Markey, S.P. (1986) 1-methyl-4-phenyl-pyridine (MPP +) induces oxidative stress in the rodent. Life Sci. 38:743–749.PubMedCrossRefGoogle Scholar
  17. Langston, J. W., Ballard, P, Tetrud, J. W. and Irwin, I. (1983) Chronic parkinsonism in humans due to a product of meperidine-analogue synthesis. Science 219:979–980.PubMedCrossRefGoogle Scholar
  18. Langston, J.W., Forno, L.S., Rebert, C.S. and Irwin, I. (1984a) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292: 390–394.PubMedCrossRefGoogle Scholar
  19. Langston, J. W., Irwin, I., Langston, E. B. and Forno, L. S. (1984b) Pargyline prevents MPTP-induced parkinsonism in primates. Science, 225, 1480–1482.PubMedCrossRefGoogle Scholar
  20. Martinovits, G., Melamed, E., Cohen, 0., Rosenthal, J. andUzzan, A. (1986) Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci. Lett. 69:192–197.PubMedCrossRefGoogle Scholar
  21. Mytilineou, C. (1987) Tissue culture studies of aging in the nervous system: toxicity of MPTP to dopamine neurons. In Vernadakis, A. (ed.), “Model Systems of Development and Aging of the Nervous System”, pp. 491–500, Martinus Nijhoff.CrossRefGoogle Scholar
  22. Mytilineou, C. and Cohen, G. (1984) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. Science, 225:529–531.PubMedCrossRefGoogle Scholar
  23. Mytilineou, C., Cohen, G. and Heikkila, R. E. (1985) 1-methyl-4-phenylpyridine (MPP +) is toxic to mesencephalic dopamine neurons in culture. Neurosci. Lett. 57:19–24.PubMedCrossRefGoogle Scholar
  24. Perry, T.L., Yong, V. W., Clavier, R.M., Jones, K., Wright, J.M., Foulks, J.G. and Wall, R. A. (1985) Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60:109–114.PubMedCrossRefGoogle Scholar
  25. Sachs, Ch., Jonsson,.G., Heikkila, R. and Cohen, G. (1975) Control of the neurotoxicity of 6-hydroxydopamine by intraneuronal noradrenaline in rat iris. Acta Physiol. Scand. 93:345–351.PubMedCrossRefGoogle Scholar
  26. Salach, J.I., Singer, T.P., Castagnoli, N. and Trevor, A. (1984) Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem. Biophys. Res. Commun. 125:831–835.PubMedCrossRefGoogle Scholar
  27. SanchezRamos, J.R., Barrett, J.N., Goldstein, M., Weiner, W.J. and Hefti, F. (1986) 1-methyl-4-phenyl-pyridinium (MPP+) but not 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) selectively destroys dopaminergic neurons in cultures of dissociated rat mesencephalic neurons. Neurosci. Lett., 72:215–220.PubMedCrossRefGoogle Scholar
  28. Schmidt, C. J., Bruckwick, E. and Lovenberg, W. (1985) Lack of evidence supporting a role for dopamine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Eur. J. Pharmacol. 113:149–150.PubMedCrossRefGoogle Scholar
  29. Schmidt, C.J., Ritter, J.K., Sonsalla, P.K., Hanson, G.R. and Gibb, J.W. (1985) The role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233:539–544.PubMedGoogle Scholar
  30. Singer, T.P., Salach, J.I. and Crabtree, D. (1985) Reversible inhibition and mechanism-based irreversible inactivation of monoamine oxidases by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem. Biophys. Res. Comm. 127:707–712.CrossRefGoogle Scholar
  31. Sonsalla, P.K. and Heikkila, R.E. (1986) The influence of dose and dosing interval on MPTP induced dopaminergic neurotoxicity. Eur. J. Pharmacol. 129:339–345.PubMedCrossRefGoogle Scholar
  32. Tipton, K.F., McCrodden, J.M. and Youdim, M.B.H. (1986) Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem. J. 240:379–383.PubMedGoogle Scholar
  33. Youdim, M.B.H. (1975) Assay and purification of brain monoamine oxidase. In "Research methods in Neurobiology" Vol. 3, p.p. 167–207 (Marks, N. Rodnight, R. Eds.) New York, Plenum.Google Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Catherine Mytilineou
  • Linda K. Friedman
    • 1
  • Peter Danias
    • 1
  1. 1.Department of NeurologyMount sinai School of MedicineNew YorkUSA

Personalised recommendations